Home
Posts
At the Core of the Latest Pharm-to-Table Dispute: Which GLP-1 Was Hims Preferring?

At the Core of the Latest Pharm-to-Table Dispute: Which GLP-1 Was Hims Preferring?

And a veritable deluge of data about benefit design has me thinking about the impact on PBMs ... and patients

Jun 24, 2025

Subscribe to Cost Curve Apex to read the rest.

Upgrade to Apex to get access to this post and other subscriber-only content.

No posts found